Corbus Pharmaceuticals, Inc.
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Employees
- 1
- Market Cap
- $689.3M
- Website
- http://www.corbuspharma.com
Clinical Trials
53
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (53 trials with phase data)• Click on a phase to view related trials
First-in-human Study of CRB-601-01 to Treat Patients With Advanced Solid Tumor.
- Conditions
- Solid Tumor
- Interventions
- Drug: CRB-601 monoclonal antibodyDrug: Anti-PD-1 monoclonal antibody
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2025-06-03
- Lead Sponsor
- Corbus Pharmaceuticals Inc.
- Target Recruit Count
- 156
- Registration Number
- NCT06603844
- Locations
- 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸SCRI - Arizona Oncology Associates, Tucson, Arizona, United States
🇺🇸The University of Arizona Cancer Center, Tucson, Arizona, United States
A Phase 1/2 Study to Investigate CRB-701 in Solid Tumors
- First Posted Date
- 2024-02-20
- Last Posted Date
- 2025-06-03
- Lead Sponsor
- Corbus Pharmaceuticals Inc.
- Target Recruit Count
- 348
- Registration Number
- NCT06265727
- Locations
- 🇺🇸
O'Neal Comprehensive Cancer Center at University of Alabama-Birmingham, Birmingham, Alabama, United States
🇺🇸City of Hope Cancer Center, Duarte, California, United States
🇺🇸Moores Cancer Centre at UC San Diego Health, San Diego, California, United States
Trial to Evaluate Efficacy and Safety of Lenabasum in Dermatomyositis
- Conditions
- Dermatomyositis
- Interventions
- First Posted Date
- 2019-01-23
- Last Posted Date
- 2022-08-16
- Lead Sponsor
- Corbus Pharmaceuticals Inc.
- Target Recruit Count
- 176
- Registration Number
- NCT03813160
- Locations
- 🇺🇸
HonorHealth Neurology, Phoenix, Arizona, United States
🇺🇸Mayo Clinic, Jacksonville, Florida, United States
🇺🇸Attune Health Center, Beverly Hills, California, United States
Trial to Evaluate Efficacy and Safety of Lenabasum in Cystic Fibrosis
- Conditions
- Cystic Fibrosis
- Interventions
- First Posted Date
- 2018-03-01
- Last Posted Date
- 2023-01-18
- Lead Sponsor
- Corbus Pharmaceuticals Inc.
- Target Recruit Count
- 447
- Registration Number
- NCT03451045
- Locations
- 🇺🇸
Phoenix Children's Hospital, Phoenix, Arizona, United States
🇺🇸University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
🇺🇸Miller Children's Hospital, Long Beach, California, United States
Trial to Evaluate Efficacy and Safety of Lenabasum in Diffuse Cutaneous Systemic Sclerosis
- Conditions
- Diffuse Cutaneous Systemic Sclerosis
- Interventions
- First Posted Date
- 2018-01-16
- Last Posted Date
- 2021-03-29
- Lead Sponsor
- Corbus Pharmaceuticals Inc.
- Target Recruit Count
- 365
- Registration Number
- NCT03398837
- Locations
- 🇺🇸
University of California San Diego, La Jolla, California, United States
🇺🇸Pacific Arthritis Care Center, Los Angeles, California, United States
🇺🇸UCLA, Los Angeles, California, United States
- Prev
- 1
- 2
- Next